Rockefeller Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Rockefeller Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-733	Closed	-$4.08K	–	4813
2026 Q1	$4.08K	Hold	733	–	–	﹤0.01%	4281
2025 Q4	$5.39K	Buy	+733	New	+$4.48K	﹤0.01%	4049
2022 Q3	–	Sell	-60	Closed	-$4K	–	4150
2022 Q2	$4K	Sell	60 -167	-74%	-$15.3K	﹤0.01%	3553
2022 Q1	$25K	Sell	227 -46	-17%	-$5.73K	﹤0.01%	2622
2021 Q4	$26K	Buy	273 +26	+11%	+$2.59K	﹤0.01%	2517
2021 Q3	$21K	Buy	247 +20	+9%	+$2.08K	﹤0.01%	2570
2021 Q2	$35K	Hold	227	–	–	﹤0.01%	2237
2021 Q1	$35K	Buy	227 +80	+54%	+$16.9K	﹤0.01%	2045
2020 Q4	$34K	Buy	147 +129	+717%	+$29.9K	﹤0.01%	1809
2020 Q3	$3K	Buy	18 +7	+64%	+$1.71K	﹤0.01%	2338
2020 Q2	$3K	Buy	+11	New	+$3.25K	﹤0.01%	2236

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rockefeller Capital Management's KPTI Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 733 shares — an estimated $4.08K sold.

Rockefeller Capital Management first reported a position in KPTI in Q2 2020 and held it in 11 quarters. The position peaked at $35K in Q2 2021. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Rockefeller Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
Rockefeller Capital Management sold 733 Karyopharm Therapeutics shares in Q2 2026, an estimated $4.08K.
Rockefeller Capital Management first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 11 quarters.
Rockefeller Capital Management's Karyopharm Therapeutics position peaked at $35K in Q2 2021.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.